Compass Therapeutics Inc.

NASDAQ CMPX

Data sourced from iex and EODHD
Download Data

Compass Therapeutics Inc. Income Statement 2018 - 2024

This table shows the Income Statement for Compass Therapeutics Inc. going from 2018 until 2024. The income statement, also known as the profit and loss statement, is a financial statement that provides a summary of a company's revenues, expenses, and net income over a specific period (such as a quarter or a year). It shows the company's ability to generate revenue, manage expenses, and ultimately determine its profitability.
Income Statement Trend Unit 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2018-06-30
Revenue
M 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 - - - -
Cost of Revenue
M 0 0 0 0 0 0 - - - - - - - - - - - - - - -
Gross Profit
M 0 2 0 0 0 0 - - - - - - - - - - - - - - -
Operating Expenses
M 12 18 11 13 9 12 - - - - - - - - - - - - - - -
Selling, General, and Administrative Expenses (SG&A)
M 3 3 3 3 3 3 3 3 3 3 3 2 3 4 5 2 2 3 2 3 -
Research and Development (R&D) Expenses
M 9 12 9 10 7 10 10 6 4 10 3 3 5 4 4 3 4 3 6 5 -
Other Operating Expenses
M 0 3 0 0 0 0 - - - - - - - - - - - - - - -
Costs and Expenses
M 12 14 11 13 9 12 - - - - - - - - - - - - - - -
Operating Income
M -13 -15 -12 -13 -10 -13 -13 -9 -7 -13 -6 -56 -7 -8 -9 -5 -6 -6 -8 -9 -
Interest Expense
M - 2 - - 2 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 -
Non-operating Income/Expense
M 2 2 2 2 2 1 1 0 0 0 0 -51 0 0 0 0 0 0 0 0 -
EBT
M -11 -13 -10 -11 -8 -12 -12 -8 -7 -13 -6 -56 -7 -8 -9 -6 -6 -7 -9 -9 0
Income Tax Provision
M - 2 - - -2 -1 -1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Income after Tax
M - -15 - - -6 -10 -11 -8 -7 -13 -6 -56 -8 -9 -9 -6 -6 -7 -9 -9 0
Non-Controlling Interest
M - - - 0 0 0 0 0 0 0 0 0 0 0 0 0 - - - - -
Net Income
M - - - -11 -8 -12 -12 -8 -7 -13 -6 -56 -7 -8 -9 -6 - - - - -
Shares (Basic, Weighted)
M - - - - - - - - - - - - - - - - - - - - -
Shares (Diluted, Weighted)
R 136,608,000.00 127,668,000.00 127,424,000.00 126,729,000.00 126,375,000.00 105,186,000.00 101,010,000.00 100,947,000.00 100,858,000.00 51,913,000.00 61,694,000.00 51,913,000.00 51,313,000.00 61,120,062.00 61,120,062.00 52,112,143.00 52,112,143.00 61,120,062.00 52,112,143.00 52,112,143.00 -
EBITDA
M -12 -15 -11 -13 -9 -11 -11 -8 -7 -13 -5 -5 -7 -7 -9 -5 -5 -6 -8 -8 -
Depreciation and Amortization
M 0 0 0 0 0 2 1 1 0 0 0 0 0 1 0 0 0 1 1 0 -
EBIT
M -13 -15 -12 -13 -10 -13 -13 -9 -7 -13 -6 -5 -7 -8 -9 -5 -6 -6 -8 -9 -
Income from Discontinued Operations
M - - - - - - - - - - - - - - - - - - - - -
Tax Rate (Effective)
% - -13.97 - - 23.91 11.16 5.20 5.80 0.28 0.10 -0.57 -0.02 -1.91 -2.12 -2.32 -0.29 -0.25 -0.15 -0.30 -0.30 100.00
Earnings Per Share (EPS), Basic
M - - - - - - - - - - - - - - - - - - - - -
Earnings Per Share (EPS), Diluted
M - - - 0 0 0 0 0 0 0 0 0 0 0 0 0 - - - - -
Gross Profit Margin
% - 83.54 - - - - - - - - - - - - - - - - - - -
Operating Income Margin
% - -541.24 - - - - - - - - - - - - - - - - - - -
Net Income Margin
% - - - - - - - - - - - - - - - - - - - - -
EBITDA Ratio
% - -524.79 - - - - - - - - - - - - - - - - - - -
EBIT Ratio
% - -541.24 - - - - - - - - - - - - - - - - - - -
EBT Ratio
% - -471.69 - - - - - - - - - - - - - - - - - - -

StockViz Staff

September 16, 2024

Any question? Send us an email